Positron Emission Tomography (PET) radiotracers in oncology - Utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)

Journal of Experimental and Clinical Cancer Research

Volumn 27, Issue 1, 2008, Pages

  Miele, Evelina ^a,c   Spinelli, Gian Paolo ^a,c   Tomao, Federica ^a,c   Zullo, Angelo ^b,c   De Marinis, Filippo ^b,c   Pasciuti, Giulia ^a,c   Rossi, Luigi ^a,c   Zoratto, Federica ^a,c   Tomao, Silverio ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

16 BETA FLUORO 5 DIHYDROTESTOSTERONE F 18; 3 FLUORO 3 DEOXYTHYMIDINE F 18; ACETIC ACID C 11; ANTINEOPLASTIC AGENT; CHOLINE C 11; FLOURIDE F 18; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; LEVODOPA F 18; METHIONINE C 11; SOMATOSTATIN DERIVATIVE; SUNITINIB; TRACER; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CAUSE OF DEATH; DRUG HALF LIFE; DRUG UPTAKE; FOLLOW UP; HUMAN; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; LUNG TUMOR; LYMPH NODE METASTASIS; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 55349140431     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-27-52     Document Type: Review

References (98)

1. Conventional and novel PET tracers for imaging in oncology in the era of molecular therapy. MA Pantaleo M Nannini A Maleddu, Cancer Treat Rev 2008 34 2 103 21 10.1016/j.ctrv.2007.10.001 18055120
2. The rate-limiting step for tumor [18F]fluoro-2-deoxy-Dglucose (FDG) incorporation. TA Smith, Nucl Med Biol 2001 28 1 1 4 10.1016/S0969-8051(00) 00177-3 11182558
3. Summary of the standards options and recommendations for the use of Positron Emission Tomography with 2-[18F] Fluoro-2-deoxy-d-Glucose (FDG-PET scanning) in Oncology. P Bourguet MP Blanc-Vincent A Boneu L Bosquet, BJC 2003 89 S84 S91 12915907
4. 18Fluorodeoxyglucose Positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. YC Ung DE Maziak, J Natl Cancer Inst 2007 99 23 1753 1767 10.1093/jnci/djm232 18042932
5. A fluorinate glucose analogue, 2-fluoro-2-deoxy-D-Glucose (F-18): nontoxic tracer for rapid tumour detection. P Son HE Atkins, J Nucl Med 1980 21 670 675 7391842
6. Transport of sugars in tumor cell membranes. M Hatanaka, Biochim biophys acta 1974 355 77 104 4371599
7. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. R Kubota K Kubota S Yamada, J Nucl Med 1994 35 104 112 8271030
8. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. W Okumura T Iwasaki T Toyama, 2004 45 1989 1998 15585472
9. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. K Higashi Y Ueda H Seki, J Nucl Med 1998 39 1016 1020 9627336
10. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDGPET. T Torizuka N Tamaki T Inokuma, J Nucl Med 1995 36 1811 1817 7562048
11. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Keigo Endo Noboru Oriuchi Tetsuya Higuchi Yasuhiko Iida Hirofumi Hanaoka Mitsuyuki Miyakubo Tomohiro Ishikita Keiko Koyama, Int J Clin Oncol 2006 11 286 296 10.1007/s10147-006-0595-0 16937302
12. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. SS Shin, Radiology 2005 236 1011 1019 10.1148/radiol.2363041310 16014441
13. Measurement of clinical and subclinical tumour response using 18 Fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. H Young R Baum U Cremerius, Eur J Cancer 1999 35 1773 1782 10.1016/S0959-8049(99)00229-4 10673991
14. Procedure guideline for tumour imaging with 18F-FDG PET/CT 1.0. D Delbeke RE Coleman MJ Guberteau, J Nucl Med 2006 47 885 895 16644760
15. The use of PET in Parkinson's disease. H Shinotoh DB Calne, Brain Cogn 1995 28 297 310 10.1006/brcg.1995.1259 8546856
16. Limited value of Fluorine-18 fluorodeoxy-glucose positron emission tomography for the imaging of neuroendocrine tumors. S Adams R Baum T Rink, Eur J Nucl Med 1998 25 79 83 10.1007/s002590050197 9396878
17. The present and future role of 111In Pentetreotide in the PET era. PF Rambaldi V Cuccurullo V Briganti L Mansi, J Nucl Med Mol Imag 2005 49 225 35
18. Studies of human tumors by MRS: a review. W Negendank, NMR biomed 1992 5 303 324 1333263
19. Over expression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate and human colorectal cancers. A Ramirez De Molina A Rodriguez-Gonzales, Biochem Biophys Res Commum 2002 296 580 583 10.1016/S0006-291X(02)00920-8
20. PET imaging of prostate cancer using carbon-11-choline. T Hara N Cosaka H Kishi, J Nucl Med 1998 39 990 995 9627331
21. Sensitive detection of mediastinal lymph node metastases of lung cancer with 11C-Choline PET. T Hara K Inagaki N Cosaka T Morita, J Nucl Med 2000 41 9 1507 13 10994730
22. Value of 11C-Choline-positron emission tomography for restaging prostate cancer: a comparison with 18F-Fluorodeoxyglucose positron emission tomography. M Picchio C Messa C Landoni, J Urol 2003 169 1337 1340 10.1097/01.ju.0000056901. 95996.43 12629355
23. Positive 11c-choline and negative 18F-FDG with positron emission tomography in recurrence of prostate cancer. M Picchio C Landoni C Messa, AJR Am J Roentgenol 2002 179 482 484 12130458
24. Positron Tomographic assessment of androgen receptors in prostatic carcinoma. F Dehdashti J Picus JM Michalski, Eur J Nucl Med Mol Imag 2005 32 344 350 10.1007/s00259-005-1764-5
25. Validation of FLT uptake as a measure of thymidine-kinase-1 activity in A549 carcinoma cells. JS Rasey JR Grierson LW Wiens, J Nucl Med 2002 43 1210 1217 12215561
26. 18-FLT PET for diagnosis and staging of thoracic tumors. H Dittman BM Dohmen F Paulsen, Eur J Nucl Med Mol Imag 2003 30 1407 1412 10.1007/s00259-003- 1257-3
27. Potential impact of 18-F-3-Fluoro-3-deoxy-thymidine versus 18-F-Fluoro-2-deoxy-D-glucose in positron emission tomography for colorectal cancer. DL Francis D Visviskis DC Costa, Eur J Med Mol Imag 2003 30 988 994 10.1007/s00259-003-1187-0
28. Detection and grading of soft tissue sarcomas of the extremities with 18-F-3-Fluoro-3-deoxy-L-Thymidine. DC Cobben PH Elsinga AJ Suurmeijer, Clin Canc Res 2004 10 1685 1690 10.1158/1078-0432.CCR-03-0040
29. 18-F-3-Fluoro-3-deoxy-thymidine and 11C-methyilmetionine as markers of increased transport and proliferation in brain tumor. AH Jacobs A Thomas LW Kracht, J Nucl Med 2005 46 1948 1958 16330557
30. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. M Yoshimoto A Waki Y Yonekura, Nucl Med Biol 2001 28 117 122 10.1016/S0969-8051(00)00195-5 11295421
31. [1-(11) C] Acetate uptake is not increased in renal cell carcinoma. J Kotzerke C Linne' M Meinhardt, Eur J Nucl Med Mol Imag 2007 32 884 888 10.1007/s00259-006-0362-5
32. 11CAcetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. N Oyama TR Miller F Dehdashti, J Nucl Med 2003 44 549 555 12679398
33. 11C-Acetate: a new tracer for the evaluation of hepatocellular carcinoma. D Delbeke CV Pinson, J Nucl Med 2003 44 222 223 12571213
34. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. CL Ho S Chen DV Yeung TK Cheng, J Nucl Med 2007 48 902 909 10.2967/jnumed.106.036673 17504862
35. Fluoridine kinetics of the axial skeleton measured in vivo with fluorine-18-fluoride PET. C Schiepers J Nuyts G Bormans, J Nucl Med 1997 38 1970 1976 9430479
36. Combined FDG and 18F-Fluoride whole-body PET: a feasible two in one approach to cancer imaging? S Hoegerle F Juenglin A Otte, Radiology 1998 209 253 258 9769840
37. 11-C-methionine PET, histopathology, and survival in primary brain tumors and recurrence. S Ceyssens K Van Laere T de Groot, AJNR 2006 27 1432 1437 16908552
38. Role of 11-C Methionine positron emission tomography for the delineation of the tumor volume in pharyngo-laryngeal squamous cell carcinoma: comparison with FDG PET and CT. X Geets JF Daise V Gregoire, Radiother Oncol 2004 71 267 273 10.1016/j.radonc.2004.02.013 15172141
39. Detection of prostate cancer with 11-C methionine positron emission tomography. G Thot Z Lengyel L Balkay, J Urol 2005 173 66 69 15592030
40. nd edition). LA Robinson JC Ruckdeschel H Wagner Jr CW Stevens, Chest 2007 132 suppl 3 243S 245S 10.1378/chest.07-1379
41. A Ernst D Anantham R Eberhardt M Kranik FJF Herth, J Thorac Oncol 2008 3 577 82 10.1097/JTO.0b013e3181753b5e 18520794
42. Endoscopic Ultrasound-Guided Fine-Needle Aspiration for Non-small Cell Lung Cancer Staging: A Systematic Review and Metaanalysis. Jowell Frank G Gress Carlos G Micames Douglas C McCrory Darren A Pavey S Paul, Chest 2007 131 539 548 10.1378/chest.06-1437 17296659
43. Routine mediastinoscopy and esophageal ultrasound fine-needle aspiration in patients with non-small cell lung cancer who are clinically N2 negative: a prospective study. RJ Cerfolio AS Bryant MA Eloubeidi, Chest 2006 130 1791 5 10.1378/chest.130.6.1791 17166998
44. Should mediastinoscopy be routine for patients with clinical stage I lung cancer screened by CT and PET scans? A decision analysis. FJ Haddad BF Meyers JB Zoole, Presented at the American Association of Thoracic Surgeons 2005, April 29 2005 to May 3 2006, Philadelphia PA. J Cardio-Thorac Surg 2006
45. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable non-small celllung cancer? KH Kernstine KA Mclaughlin Y Menda, Ann Thorac Surg 2002 73 394 401 10.1016/S0003-4975(01)03432-4 11845848
46. The non invasive staging of non-small cell lung cancer: the guidelines. GA Silvestri LT Tanoue ML Margolis J Barker F Detterbeck American College of Chest Physicians, Chest 2003 123 1 Suppl 147S 156S 10.1378/chest.123.1_suppl. 147S 12527574
47. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. RM Pieterman JW van Putten JJ Meuzelaar, N Engl J Med 2000 343 254 261 10.1056/NEJM200007273430404 10911007
48. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. T Bury A Dowlati P Paulus, Eur Respir J 1997 10 2529 2534 10.1183/09031936.97.10112529 9426090
49. How useful is positron emissiontomography for lymphnode staging in non-small-cell lung cancer? F Liewald S Grosse M Storck, Thorac Cardiovasc Surg 2000 48 93 96 10.1055/s-2000-9870 11028710
50. Staging non-small cell lung cancer with wholebody PET. EM Marom HP McAdams JJ Erasmus, Radiology 1999 212 803 809 10478250
51. PET-FDG scan enhances butdoes not replace preoperative surgical staging in non-small cell lung carcinoma. AJ Poncelet M Lonneux E Coche, Eur J Cardiothorac Surg 2001 20 468 474 10.1016/S1010-7940(01)00827-2 11509265
52. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. PE Valk TR Pounds DM Hopkins, Ann Thorac Surg 1995 60 1573 1581 10.1016/0003-4975(95)00752-0 8787446
53. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. H Vesselle JM Pugsley E Vallieres, J Thorac Cardiovasc Surg 2002 124 511 519 10.1067/mtc.2002.123130 12202868
54. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. DW Von Haag DM Follette PF Roberts, J Surg Res 2002 103 160 164 10.1006/jsre.2002.6354 11922730
55. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. H van Tinteren OS Hoekstra EF Smit, Lancet 2002 359 1388 1393 10.1016/S0140-6736(02)08352-6 11978336
56. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. CE Reed DH Harpole KE Posther American College of Surgeons Oncology Group Z0050 trial, J Thorac Cardiovasc Surg 2003 126 1943 1951 10.1016/j.jtcvs.2003.07.030 14688710
57. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. BM Fischer J Mortensen L Hojgaard, Lancet Oncol 2001 2 659 666 10.1016/S1470-2045(01)00555-1 11902536
58. Nonivasive staging of non-small cell lung cancer: a review of current evidence. EM Toloza L Harpole DC McCrory, Chest 2003 123 Suppl 1 137S 146S 10.1378/chest.123.1_suppl.137S
59. Metastases from non small cell lung cancer: mediastinal staging in the 1990s - meta-analytic comparison of PET and CT. BA Dwamena SS Sonnad JO Angobaldo RL Wahl, Radiology 1999 213 530 536 10551237
60. Meta analysis of the efficacy of Positron Emission Tomography with F-18-Fluorodeoxyglucose in lung tumours: basis for discussion of the German Consensus Conference on PET in Oncology 2000. D Hellwig D Ukena F Paulsen M Bamberg CM Kirsch, Pneumologie 2001 55 367 377 10.1055/s-2001-16201 11505288
61. Test performance of Positron Emission Tomography and Computed Tomography for mediastinal staging in patients with non small cell lung cancer: a meta analysis. MK Gould WG Kuschner CE Rydzak, Ann Intern Med 2003 139 879 892 14644890
62. Meta analysis of Positron Emission Tomographic and Computed Tomographic imaging in detecting mediastinal lymph node metastases in Non small cell lung cancer. O Birim AP Kappetein T Stijnen AJ Bogers, Ann Thorac Surg 2005 79 375 382 10.1016/j.athoracsur.2004.06.041 15620991
63. Lymph node size and metastatic infiltration in non small cell lung cancer. KL Prenzel SP Monig JM Sinning SE Baldus HG Brochhagen PM Schneider, Chest 2003 23 463 7 10.1378/chest.123.2.463
64. FDG-PET in staging lung cancer. How does it change the algorithm? AFT Verhagen GP Bootsma VCG Tjan-Heijnen GJ van der Wilt AL Cox MHJ Brouwer FHM Corstens WJG Oyen, Lung Cancer 2004 44 175 181 10.1016/j.lungcan.2003.11.007 15084382
65. Lymph node staging in non-small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. JF Vansteenkiste SG Stroobants PR De Leyen PJ Dupont J Bogaert A Maes, J Clin Oncol 1998 16 2142 9 9626214
66. How to optimize staging in early non-small cell lung cancer. JR Jett, Lung Cancer 2002 38 S13 6 10.1016/S0169-5002(02)00246-5 12367808
67. Current Concepts in the Mediastinal Lymph Node Staging of Nonsmall Cell Lung Cancer. H Kramer JM Groen, Annals of Surgery 2003 238 2 12894010
68. mediastinal nodal staging of Non small cell lung cancer using integrated 18-F-FDG PET/CT in a tuberculosis endemic country. YK Kim KS Lee BT Kim JY Choi H Kim OJ Kwon YM Shim CA Yi HY Kim MJ Chung, Cancer 2007 109 1068 77 10.1002/cncr.22518 17311309
69. Mediastinal lymph node staging in suspected lung cancer: comparison of positron emission tomography with F-18-fluorodeoxyglucose and mediastinoscopy. TP Graeter D Hellwig K Hoffmann D Ukena C Kirsch H Schäfers, Ann Thorac Surg 2003 75 231 6 10.1016/S0003-4975(02)04350-3 12537221
70. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. N Al-Sarraf R Aziz K Gately J Lucey L Wilson E McGovern V Young, Eur J Cardio-thoracic Surgery 2008 33 104 109 10.1016/j.ejcts.2007.09.026
71. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. SS Shim KS Lee BT Kim MJ Chung EJ Lee J Han, Radiology 2005 236 1011 1019 10.1148/radiol.2363041310 16014441
72. The role of PET scan in diagnosis, staging and management of non-small cell lung cancer. L Schrevens N Lorent C Dooms J Vansteenkiste, Oncologist 2004 9 633 643 10.1634/theoncologist.9-6-633 15561807
73. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with non-small cell lung cancer. RJ Cerfolio B Ojha AS Bryant V Raughuveer JM Mountz AA Bartolucci, Ann Thorac Surg 2004 78 1017 23 10.1016/j.athoracsur.2004.02.067 15337041
74. Presurgical staging of non small cell lung cancer: Positron Emission Tomography, integrated Positron Emission Tomography/CT, and software image fusion. Bs Halpern C Schiepers WA Weber, Chest 2005 128 2289 2297 10.1378/chest.128.4.2289 16236886
75. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative results. M Dietlein K Weber A Gandijour, Eur J Nucl Med 2000 27 1598 1609 10.1007/s002590000376 11105815
76. Cost-effectiveness of routine mediastinoscopy in computed tomography- and positron emission tomography-screened patients with stage I lung cancer. BF Meyers F Haddad BA Siegel JB Zoole RJ Battafarano N Veeramachaneni JD Cooper GA Patterson, J Thorac cardiovasc Surg 2006 131 4 822 9 10.1016/j.jtcvs.2005.10.045 16580440
77. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. RJ Cerfolio S Bryant B Ohja AA Bartolucci, J Thorac Cardiovasc Surg 2005 130 1 151 9 10.1016/j.jtcvs.2004.11.007 15999056
78. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. BE Lee J Redwine C Foster E Abella T Lown D Lau D Follette, J Thorac Cardiovasc Surg 2007 3 135 615 619
79. Can PET/CT replace separate diagnostic CT for cancer imaging? Optimizing CT protocols for imaging cancers of the chest and abdomen. H Kuehl P Veit SJ Rosenbaum A Bockisch G Antoch, J Nucl Med 2007 48 45S 57S 17204720
80. PET-based treatment planning in radiotherapy: a new standard? V Grègoire K Haustermans X Geets S Roels M Lonneux, J Nucl Med 2007 48 68S 77S 17204722
81. Selective mediastinal node irradiation based on FDG PET scan data in patients with non small cell lung cancer: a prospective clinical study. D De Ruysscher S Vanders E van haren, Int J radiat Oncol Biol Phys 2005 62 988 994 15989999
82. 18FDG PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. J Van Loon C Offermann G Bosmans R Wanders A Dekker, Radiother Oncol 2008 18342967
83. Increased terapeutic ratio by 18FDG PET/CT planning in patients with clinical CT stage N2-N3 M0 non-small-cell lung cancer: a medeling study. A Van der Wel S Nijsten M Hochstenbag, Int J Radiat Oncol Biol Phys 2005 61 649 655 15708242
84. value of 18FDG PET/CT in non small cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemo-radiotherapy. C Potgen S Levegrun D Theegarten, Clin Cancer Res 2006 12 97 106 10.1158/1078-0432.CCR-05-0510 16397030
85. Use of PET to monitor the response of lung cancer to radiation treatment. YE Erdi H Macapinlac KE Rosenweig, Eur J Nucl Med 2000 27 861 866 10.1007/s002590000258 10952499
86. PET scanning in lung cancer: current status and future directions. MP Macmanus RJ Hicks, Sem Surg Oncol 2003 21 149 155 10.1002/ssu.10032
87. Uptade in PET imaging of non small cell lung cancer. EM Rohren VJ Lowe, Sem Nucl Med 2004 34 134 153 10.1053/j.semnuclmed.2003.12.004
88. PET in oncology: Basics and clinical application. J Ruhlmann P Oehr HJ Biersack, New York, NY: Springer 1999 102 119
89. Value of FDG PET in the management of non small cell lung cancer. S Stoobants J Verschakelen J Vansteenkiste, Eur J Radiol 2003 45 49 59 10.1016/S0720-048X(02)00282-6 12499064
90. Value of FDG PET in detecting residual or recurrent non small cell lung cancer. T Bury JL Corhay B Duysinx, Eur Respir J 1999 14 1376 1380 10.1183/09031936.99.14613769 10624770
91. Prognostic stratification of stage IIIA-N2 non small cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumour response on serial 18-Fluoro-2-deoxyglucose Positron Emission Tomography. C Dooms E Verbeken S Stroobants K nackaerts P de Leyn J Vansteenkiste, J Clin Oncol 2008 26 1128 1134 10.1200/JCO.2007.13.9550 18309948
92. Practical FDG imaging: a teaching File. D Delbeke WH Martin JA Patton MP Sandler, New York, NY: Springer 2002 150 188
93. Regular follow-up after curative resection of nonsmall cell lung cancer: a real benefit for patients? U Egermann K Jaeggi JM Habicht AP Perruchoud P Dalquen M Soler, Eur Respir J 2002 19 464 8 10.1183/09031936.02.00231802 11936523
94. Second surgical intervention for recurrent and second primary bronchogenic carcinomas. Y Watanabe J Shimizu M Oda Y Tatsuzawa Y Hajashi T Iwa, Scand J Thorac Cardiovasc Surg 1992 26 73 8 1529302
95. 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. Z Keidar N Haim L Guralnik, J Nucl Med 2004 45 1640 1646 15471827
96. The utility of 18F-FDG for suspected recurrent NSCLC after potentially curative therapy: impact on management and prognostic stratification. RJ Hicks V Kalff MP MacManus RE Ware AF McKenzie JP Matthews, J Nucl Med 2001 42 11 1605 1613 11696628
97. Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer. D Hellwig A Gröschel TP Graeter AP Hellwig U Nestle HJ Schäfers GW Sybrecht CM Kirsch, Eur J Nucl Med Mol Imaging 2006 33 13 21 10.1007/s00259-005-1919-4 16151765
98. PET scan in the staging of non-small cell lung cancer. JF Vansteenkiste, Lung Cancer 2003 42 S27 S37 10.1016/S0169-5002(03)00302-7 14611912